SSTR4
Somatostatin receptor type 4
As of the edition of 20 October 2026, SSTR4 (somatostatin receptor type 4, UniProt P31391) has 7 drugs tested at it and 14 companies on the list, 2 on route A and 4 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P31391
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Cancer; Hormones; Digestive system; Nervous system; Bones, joints and muscles; Nutrition and metabolism; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 261
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 1 |
| Withdrawn from market | 1 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Octreotide | Marketed | Phase 4 | none listed |
| Lutetium oxodotreotide | Marketed | Phase 4 | Ends 2031 |
| Somatostatin | Marketed | Phase 4 | none listed |
| Veldoreotide | Went quiet | Phase 2 | none listed |
| Indium pentetreotide | Marketed | Phase 4 | none listed |
| Lutetium-177 | Status not established | No phase stated | none listed |
| Lutetium chloride | Withdrawn from market | No phase stated | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 4 |
| Engaged | 3 |
| Undetermined | 5 |
| Total on the list | 14 |
| Company | Route |
|---|---|
| Curium | Route B |
| Camurus | Route B |
| ITM Medical Isotopes | Route A |
The other 11 companies at SSTR4
In the product14 companies in all; 11 are not named here, and no score is.
See the 14 companies at SSTR4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.